Sino Biopharmaceutical shares rise nearly 5% on TQB6426 FDA approval
AI Summary- Sino Biopharmaceutical said Chia Tai Tianqing received U.S. FDA IND approval for TQB6426.
- TQB6426 targets GPC3 and is intended for advanced malignant tumors.
- Shares traded at HK$5.47, up 3.99%, with HK$107 million turnover.